Screener
Corcept Therapeutics CORT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income | $11,226 | $55,696 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Stock-based compensation | 52,459 | 40,853 |
| Accretion of marketable securities, net | (1,543) | (3,005) |
| Depreciation and amortization | 1,461 | 931 |
| Deferred income taxes | (10,229) | (31,469) |
| Changes in operating assets and liabilities: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's stock-based comp?
- Corcept Therapeutics (CORT) reported stock-based comp of $29.42M in Q2 2026.
- How has Corcept Therapeutics's stock-based comp changed year-over-year?
- Corcept Therapeutics's stock-based comp increased by 54.6% year-over-year, from $19.02M to $29.42M.
- What is the long-term trend for Corcept Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Corcept Therapeutics's stock-based comp has grown at a 18.4% compound annual growth rate (CAGR), from $42.93M to $84.5M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Corcept Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude